The investigators propose to conduct a clinical trial of neoadjuvant treatment utilizing chemotherapy formulations with favorable toxicity profiles: weekly doxorubicin, PPX and capecitabine. It is expected this combination will at least maintain the efficacy of a traditional chemotherapy regimen but will be associated with less toxicity, particularly nausea, vomiting and alopecia. In order to accomplish this the investigators have designed a chemotherapy regimen whose components (or administration schedule) are associated with minimal or no alopecia and are also considered to have low emetogenic potential.
In an attempt to improve the efficacy of the regimen the investigators plan to study an alternate schedule of cyclophosphamide and methotrexate administration (metronomic chemotherapy) which appears to inhibit angiogenesis and therefore enhance the activity of conventional cytotoxic chemotherapy administered concurrently.
In this trial the investigators aim to determine the clinical and pathologic response rate of 12 weeks of doxorubicin followed by 4 cycles of PPX and capecitabine. Metronomic chemotherapy with cyclophosphamide and methotrexate will be administered during the 24 weeks of chemotherapy.

Start Date01 Feb 2009

Sponsor / Collaborator

University of Southern California

[+1]

NCT00763750 / CompletedPhase 2IIT

BrUOG-Brain-223-A Phase II Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103) Principal Investigator: Howard Safran, M.D.

The purpose of this study is to determine the antitumor activity of PPX in combination with temozolomide and radiation for patients with newly diagnosed brain tumors.

Start Date01 Oct 2008

Sponsor / Collaborator

Rhode Island Hospital

[+1]

NCT00660218 / CompletedPhase 1/2IIT

A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

This study involves two phases. Phase I of this study is designed to find out the maximum dose of paclitaxel poliglumex which can be safely given to subjects when combined with cetuximab and radiotherapy in head and neck cancer. Once the maximum safe dose of paclitaxel poliglumex is found, Phase II of the study will continue to find out whether the addition of paclitaxel poliglumex increases tumor response and survival compared to treatment with cetuximab and radiotherapy alone.
An additional 20 patients have been added, to balance data. These patients must be HPV negative.

Start Date01 Mar 2008

Sponsor / Collaborator

SUNY Upstate Medical University

[+1]

100 Clinical Results associated with Paclitaxel Poliglumex

100 Translational Medicine associated with Paclitaxel Poliglumex

100 Patents (Medical) associated with Paclitaxel Poliglumex

288

Literatures (Medical) associated with Paclitaxel Poliglumex

01 Apr 2024·The ocular surface

A PEDF peptide mimetic effectively relieves dry eye in a diabetic murine model by restoring corneal nerve, barrier, and lacrimal gland function

Article

Author: Zhang, Xiaomin ; Barnstable, Colin James ; Zhao, Shaozhen ; Tombran-Tink, Joyce ; Li, Xiaorong ; Chen, Shuangping

PURPOSE:

The study investigated effectiveness of a novel PEDF peptide mimetic to alleviate dry eye-like pathologies in a Type I diabetic mouse model established using streptozotocin.

METHODS:

Mice were treated topically for 3-6 weeks with Ppx (a 17-mer PEDF mimetic) 2x/day or vehicle. Corneal sensitivity, tear film, epithelial and endothelial injury were measured using Cochet-Bonnet esthesiometer, phenol red cotton thread wetting, fluorescein sodium staining, and ZO1 expression, respectively. Inflammatory and parasympathetic nerve markers and activation of the MAPK/JNK pathways in the lacrimal glands were measured.

RESULTS:

Diabetic mice exhibited features of dry eye including reduced corneal sensation and tear secretion and increased corneal epithelium injury, nerve degeneration, and edema. Ppx reversed these pathologies and restored ZO1 expression and morphological integrity of the endothelium. Upregulation of IL-1β and TNFα, increased activation of P-38, JNK, and ERK, and higher levels of M3ACHR in diabetic lacrimal glands were also reversed by the peptide treatment.

CONCLUSION:

The study demonstrates that topical application of a synthetic PEDF mimetic effectively alleviates diabetes-induced dry eye by restoring corneal sensitivity, tear secretion, and endothelial barrier and lacrimal gland function. These findings have significant implications for the potential treatment of dry eye using a cost-effective and reproducible approach with minimal invasiveness and no obvious side effects.

01 Feb 2024·International immunopharmacology

Pramipexole protects against diabetic neuropathy: Effect on oxidative stress, TLR4/IRAK-1/TRAF-6/NF-κB and downstream inflammatory mediators

Article

Author: Helmy, Sahar A ; Eisa, Nada H ; El-Kashef, Dalia H ; El-Sherbiny, Mohamed ; Elsherbiny, Nehal M

BACKGROUND:

Diabetic neuropathy (DN) is a serious microvascular complication and a major cause of morbidity and mortality in diabetes mellitus. It is characterized by neurodegeneration of terminal sensory nerve fibers with subsequent pain, loss of sensation, and paresthesia, thus compromising the quality of life of diabetic patients. It is considered the leading cause of non-traumatic amputations worldwide, reflecting the insufficiency of current therapies. Pramipexole (PPX) is a dopamine receptor agonist used for the treatment of Parkinson's disease. The current study aims to investigate the potential neuroprotective effect of PPX in an experimental model of DN.

METHODS:

Sprague Dawley rats were randomly assigned into five groups: normal control, Normal + PPX (1 mg/kg) group, STZ control, STZ + PPX (0.25 and 1 mg/kg/day for eight weeks). The neuroprotective effect of PPX in rats was evaluated in terms of sciatic nerve histological alterations, oxidative stress, and protein expression of TLR4/MyD88/IRAK-1/TRAF-6/NF-κB axis and downstream inflammatory mediators.

RESULTS:

PPX administration ameliorated histopathological signs of neuronal inflammation and apoptosis. Additionally, PPX attenuated STZ-induced sciatic nerve oxidative stress and downregulated neural tissue expression of TLR4, MyD88, IRAK-1, TRAF-6, NF-κB and downstream mediators (TNF-α, IL-1β and ICAM-1).

CONCLUSION:

Collectively, the current study sheds light on PPX as a potential protective medication to alleviate neuropathy progression in diabetic patients. PPX neuroprotective effect can be attributed to modulating TLR4/ MyD88/IRAK-1/TRAF-6/ NF-κB axis signaling in nerve tissues with subsequent attenuation of oxidative stress and inflammation.

01 Jan 2024·Comparative biochemistry and physiology. Toxicology & pharmacology : CBP

Biochemical and teratogenic effects of a mixture of pyriproxyfen and glyphosate

Article

Author: da Silva, Josefa Gerlane ; Dos Santos Azevedo, Angélica Sabrina ; de Azevedo, Rafael David Souto ; de Oliveira Silva, Maria Regina ; de Almeida, Sinara Monica Vitalino ; Dos Santos, Jéssica Celerino ; de Sá Leitão Câmara de Araújo, Marina

The mixture of agrochemicals can be made to improve pest control or accidentally. In this way, the effects on non-target organisms are a critical aspect of the environment and heath. Thus, this work aimed to show how a mixture of pyriproxyfen, and glyphosate can impair biochemical routes and embryonic development. Zebrafish embryos 0-72 hpf were exposed to 0.001-1 μg/mL of pyriproxyfen, glyphosate, and a mixture of both pesticides. The ADMETox was evaluated in silico. The FET-test was used to estimate teratogenic effects. The biochemical effects were estimated using AChE, SOD, and CAT as parameters. ROS generation was estimated using 30 μM H₂DCF-DA and 5 μM DHE. The ADMETox reveals that intestinal absorption and P-glycoprotein are the main sites for PPx and Gly adsorption. The distribution parameters were diverse. PPx + Gly at 0.1 μg/mL leads to 50 % of lethality and at 1 μg/mL 100 % of lethality. PPx + Gly leads to a 22 % of lack of somite formation at 1 μg/mL. The heart rate was reduced by >10 % in all concentrations tested. The AChE has a decrease with IC₂₀ 19.6 μM and IC₅₀ 261.5 μM. SOD showed a reduction of 28 % to PPx and CAT was reduced by 58 % to PPx + Gly and Gly at 1 μg/mL. Glyphosate does not increase unspecific ROS generation. The superoxide generation was 2× higher in the PPx + Gly at 1 μg/mL. Summarily, was observed that the mixture of PPx + Gly potentiated the toxic effects. This finding suggests a possible synergism between the PPx and Gly even at lower concentrations.

News (Medical) associated with Paclitaxel Poliglumex

27 Jul 2023

·www.sciencedaily.com

Self-healing plastic becomes biodegradable

Chemists develop mineral plastics with numerous positive properties from sustainable basic building blocks and, together with biologists, demonstrate the material's excellent microbiological degradability. Imagine a plastic like this: harder than common plastics, non-flammable, and even with self-healing properties. But that is not all! It can be produced at room temperature in water, which is very energy-efficient and does not require toxic solvents. Before hardening, you can shape the plastic in any way you want -- like chewing gum. By adding water, it can also be converted back to its "chewing gum" form at any time, reshaped and thus recycled as often as desired. Is that impossible? No, it is not! In 2016, the research team around Konstanz chemist Helmut Cölfen presented just such a material -- a mineral plastic. However, even though the plastic, with its novel manufacturing process and outstanding material properties, has since attracted great interest from industry, it still had a crucial shortcoming from the Konstanz chemists' point of view: due to its chemical composition, it was difficult to biodegrade. A new ingredient for greater environmental compatibility "Previously, we used polyacrylic acid to produce our mineral plastic. Chemically, this acid has the same backbone as polyethylene, which is known to cause major problems in the environment because it is hardly biodegradable," explains Cölfen. The research team led by Cölfen and Ilesha Avasthi, a postdoc in Cölfen's lab, therefore set to work looking for an alternative basic building block to develop an environmentally compatible mineral plastic that retains the intriguing properties of the original material. And they found what they were looking for. In their current publication in the journal Small Methods, the Konstanz chemists present the next generation of their mineral plastic. Instead of petroleum-based ingredients such as polyacrylic acid, they now use polyglutamic acid. This natural biopolymer is readily available in large quantities and can even be obtained sustainably, for example from biotechnological production using microorganisms. A variety of microorganisms that already exist in the environment can degrade polyglutamic acid. "Our new mineral plastic has the same positive properties as the previous one, but has the decisive advantage that its basic building block -- polyglutamic acid -- can be produced with the help of microorganisms and is completely biodegradable," says Helmut Cölfen. Support from biologists In order to prove that this biodegradability also applies to the new mineral plastic itself and not just to its individual components, the chemists enlisted the support of David Schleheck and postdoc Harry Lerner from the Department of Biology at the University of Konstanz. "Helmut Cölfen has created a new type of mineral plastic in his laboratory, and our task now was to make it disappear again with the help of microorganisms," says Schleheck with a smile. In degradation experiments, the biologists were able to show that microorganisms found in forest soils, for example, began metabolizing the mineral plastic after just a few days. After only 32 days, the microorganisms had completely degraded the plastic. So the researchers have actually succeeded in making the mineral plastic with all its positive material properties now also sustainable and biodegradable.

26 Jul 2022

·www.biospace.com

Organicell Announces Matt Sinnreich as CEO

MIAMI, FL / ACCESSWIRE / July 26, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics in the extracellular vesicle space, announced today that the board of directors has appointed Matt Sinnreich as Chief Operating Officer and acting CEO. Sinnreich will replace Mr. Albert Mitrani, the founder of Organicell and CEO since September 2019, who is stepping down to serve as the Company's EVP of sales. Sinnreich, an early-stage investor in Organicell, helped fund the company's audit in 2020 to bring their financials current and was instrumental in the creation of their flagship brand: Zofin. Sinnreich comes from a development and entrepreneurial background. His track record includes profitable corporate exits, successful real estate transactions, and owner-operated residential and commercial real estate developments. Sinnreich has closed tens of millions in various financing instruments including everything from traditional real estate debt, fundraising for private companies, to collateralized derivatives and swaps. Sinnreich is an early-stage investor in the ready to drink tequila-seltzer, Mamitas and owns a minority interest in Craig's Vegan Ice Cream. Sinnreich graduated from the University of Miami Business School in 2008 where he also won the 2008 Rothschild Business Plan Competition. In response to his appointment, Sinnreich stated: "I am humbled and grateful that the board and new investment groups have entrusted me to take Organicell to the next level. I believe that exosomes are a key element in the future of medicine and this company has the team to make that a reality. Albert and Mari Mitrani are pioneers in this space. They have assembled an incredible science team, developed an amazing product line, and built top tier production labs. All the ingredients are here for this company to become a major success. As COO and acting CEO I will be focused on creating additional financing vehicles, growing the awareness of our products and brand, and most importantly maintaining an honest, transparent relationship with the shareholders. My priorities right now are to work with our CFO, Ian Bothwell, to build out Organicell's core executive team. I will pull from my network to surround myself with the best and brightest in the medical and financial arenas. I plan to create a robust ERP and data management system and to set up additional financing vehicles to fund our clinical trials. I will also be taking to market Organicell's newest biological product: Patient Pure X™ (PPX™). PPX™ is Organicell's first autologous product that is a non-manipulated biologic that concentrates a patient's exosomes from their own peripheral blood. In plain English: we can concentrate a patient's exosomes from their own blood. Organicell's science team and researchers are currently conducting studies to prove PPX's effectiveness on pain, hair loss, its potential for aesthetic uses, and surgical recovery. Organicell's products have shown promising results in the early-stage data that has been collected. Once the company has the adequate data from our clinical trials to make the claims we are studying - I believe this company will be a disrupter in the biotech industry." About Organicell Regenerative Medicines, Inc. Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. To learn more, please visit Forward-Looking Statements Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will", "believes", "expects", "potential", or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website ( ). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release. Media Contact: Joshua Rodriguez CEO and Founder CNA Finance, LLC. (503) 464-6502 SOURCE: Organicell Regenerative Medicine, Inc. View source version on accesswire.com:

100 Deals associated with Paclitaxel Poliglumex

External Link

KEGG	Wiki	ATC	Drug Bank
D05333	Paclitaxel Poliglumex	L01CD03	DB13809

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brenner Tumor	Phase 3	US	The Gynecologic Oncology Group	21 Mar 2005
Brenner Tumor	Phase 3	US	National Cancer Institute	21 Mar 2005
Endometrioid carcinoma ovary	Phase 3	US	The Gynecologic Oncology Group	21 Mar 2005
Endometrioid carcinoma ovary	Phase 3	US	National Cancer Institute	21 Mar 2005
Fallopian Tube Clear Cell Adenocarcinoma	Phase 3	US	The Gynecologic Oncology Group	21 Mar 2005
Fallopian Tube Clear Cell Adenocarcinoma	Phase 3	US	National Cancer Institute	21 Mar 2005
Mucinous Adenocarcinoma	Phase 3	US	The Gynecologic Oncology Group	21 Mar 2005
Mucinous Adenocarcinoma	Phase 3	US	National Cancer Institute	21 Mar 2005
Ovarian clear cell adenocarcinoma	Phase 3	US	National Cancer Institute	21 Mar 2005
Ovarian clear cell adenocarcinoma	Phase 3	US	The Gynecologic Oncology Group	21 Mar 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00108745 (CTgov)	Phase 3	Mucinous Adenocarcinoma \| Fallopian Tube Clear Cell Adenocarcinoma \| Ovarian mixed epithelial carcinoma ... View more	1,157	Quality-of-Life Assessment+Paclitaxel Poliglumex (Arm I (Paclitaxel Poliglumex))	nhxtelrjsy(sjnetegdms) = qjqvvolpvx bfogeputrx (dbyjuvpvhl, xpxmszhvvd - aonxmkdwag) View more	-	01 Apr 2021
				Quality-of-Life Assessment+paclitaxel (Arm II (Paclitaxel))	nhxtelrjsy(sjnetegdms) = obrxrftvjj bfogeputrx (dbyjuvpvhl, awntudwrug - ebmmdafzpa) View more
NCT00352690 (CTgov)	Phase 2	Non-small cell lung cancer stage III	10	External beam radiation therapy+Carboplatin+Paclitaxel poliglumex (Cohort 1 (First 12 Eligible Patients))	mqbvqaoeye(ebiyfwyzhk) = cwyczxukiy zlkgqgygbf (rzlshbjqje, guyaqumabm - lxxpzstunk) View more	-	27 May 2015
				External beam radiation therapy+Carboplatin+Paclitaxel poliglumex (Cohort 2 (Remaining Patients))	qbhgtaemzo(tcijsrnqeb) = udvrwfjkiy oxphannxhc (qitkwdekse, tuvnavyxit - jlcqshoasi) View more
NCT01402063 (Pubmed \| Am J Clin Oncol)	Phase 2	High grade glioma	25	Paclitaxel poliglumex	tnyahtifyl(fpzegxfxzo) = Hematologic toxicity lasted up to 5 months suggesting a drug interaction between PPX and temozolomide lzxaqmdvml (vmwqjibonj ) View more	-	01 Oct 2014
NCT00763750 (BrUOG-Brain-223, CTgov)	Phase 2	Brain Cancer	25	TMZ+PPX	dhwoltcxqi(otueixsrzq) = bzcipviryy kreghoilvq (kcoiutbqsf, votirxexpw - gcjxgiqglh) View more	-	16 Dec 2013
ASCO2012	Phase 1/2	Head and Neck Neoplasms	14	Radiation therapy	aalvudiodi(mflkllgzwd) = wzarchtqyw yrgythxgwv (xxdobabnro )	-	20 May 2012
ASCO2011	Phase 2	Non-Small Cell Lung Cancer	29	CT-2103	rxzcnpqvko(wwgupbhlcm) = yjlqcyakcn rhvqllqkuv (wbpxbptusp ) View more	Negative	20 May 2011
ASCO2011	Phase 2	High grade glioma	25	Paclitaxel poliglumex (PPX)	tzubswelud(liqhojfrvi) = kuamslbkjl hbtxwfvdhc (vqfpdazuuz ) View more	-	20 May 2011
				Temozolamide (TMZ)	tzubswelud(liqhojfrvi) = qngmgsmnsx hbtxwfvdhc (vqfpdazuuz ) View more
NCT00054197 (Pubmed \| J Thorac Oncol)	Phase 3	Advanced Lung Non-Small Cell Carcinoma	-	Paclitaxel Poliglumex (PPX)	cmwlojxeqk(qqpwtpqyqi) = spljsansjb hvylbaolkh (vkkxtnllmo ) View more	-	01 Jul 2008
				Gemcitabine or Vinorelbine	cmwlojxeqk(qqpwtpqyqi) = xyianifbsy hvylbaolkh (vkkxtnllmo ) View more
NCT00551733 (Pubmed \| J Thorac Oncol)	Phase 3	Advanced Lung Non-Small Cell Carcinoma First line	400	Paclitaxel poliglumex (PPX) + carboplatin	gdiiyjwivr(mkfwmpcwia) = wggvcuxqpt kuzqrxoeul (jlhyiimsnc ) View more	-	01 Jun 2008
				Paclitaxel + carboplatin	gdiiyjwivr(mkfwmpcwia) = urjefznxdi kuzqrxoeul (jlhyiimsnc ) View more
ASCO2008	Phase 2	Metastatic breast cancer	48	Paclitaxel polyglumex (PPX) + Capecitabine (C)	hgwqvzqgmw(dfroovvdrv) = akuiffemth ckaeotmbhw (rrbaysztky, 76–97) View more	Positive	20 May 2008

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis